CD64 + fibroblast-targeted vilanterol and a STING agonist augment CLDN18.2 BiTEs efficacy against pancreatic cancer by reducing desmoplasia and enriching stem-like CD8 + T cells.
Tianxing ZhouXupeng HouJingrui YanLin LiYongjie XieWeiwei BaiWenna JiangYiping ZouXueyang LiZiyun LiuZhaoyu ZhangBohang XuGuohua MaoYifei WangSong GaoXiuchao WangTiansuo ZhaoHongwei WangHongxia SunXiufeng ZhangXin YuChongbiao HuangJing LiuBaocun SunPublished in: Gut (2024)
Vilanterol plus the STING agonist sensitised PDAC to CLDN18.2 BiTEs and augmented efficacy as a potential novel strategy.